TUESDAY, Nov. 5 (HealthDay News) -- A new combination pill could
provide hope for hepatitis C patients who can't take or don't
respond to currently available treatments, researchers say.
The pill combines two investigational drugs, sofosbuvir and
ledipasvir, and in clinical trials it eliminated the hepatitis C
virus (HCV) in nearly all patients who took it, according to
findings published online Nov. 5 in
"Ninety-five percent of patients new to hepatitis C virus therapy who took eight weeks of the sofosbuvir/ledipasvir combination tablet were HCV undetectable 24 weeks after therapy ended, which means they are cured of HCV," said lead author Dr. Eric Lawitz, clinical professor of medicine at the University of Texas Health Science Center at San Antonio. "Similarly, among patients who had received prior therapy and took 12 weeks of sofosbuvir/ledipasvir, 95 percent were cured."
Hepatitis C, if left untreated, can cause severe and potentially
fatal liver damage. However, most people recently infected with
hepatitis C do not have symptoms. Instead, the virus causes
long-term damage, mainly scarring of the liver, a condition called
Combination drug treatments currently are available for the most
prevalent form of the virus, which affects about 75 percent of
Americans with the disease, Lawitz said. But these combination
treatments involve interferon and protease inhibitors, which can
have terrible side effects. The therapy also requires a complicated
drug regimen of pills and injections.
Fewer than half of hepatitis C patients can undergo the existing
combination therapy, given the drugs' interactions and side
effects, the authors said in background information. For those
patients, there are no treatment options at present.
"We've had nothing to offer them," said Dr. David Bernstein, chief of the division of hepatology at North Shore University Hospital in Manhasset, N.Y. "It's painted a rather bleak picture for these patients."
Sofosbuvir and ledipasvir are targeted, direct-acting agents
that interfere directly with the life cycle of the hepatitis C
virus, Lawitz said.
Researchers combined the two drugs into a single tablet taken
once a day. They recruited 100 hepatitis C patients to try the
medication, including 60 who had never received treatment and 40
who had been unsuccessfully treated using the current therapy. Some
patients also received ribavirin, currently a standard treatment,
in addition to the combination pill.
Just over half of the previously treated patients had
By 12 weeks, nearly all of the patients had achieved what
doctors call a sustained virological response, in which the virus
is eliminated and prevented from replicating -- in essence, a
"These types of advances are game-changers," Bernstein said. "We're going to be curing [very high percentages of people] with simple oral agents, one pill once a day with mild to no side effects."
About half of the patients had at least one health problem
during the study, with the highest rates seen among patients who
took ribavirin. The most common side effects were nausea, anemia,
upper respiratory tract infection and headache. The treating
physician rated most of them as mild, and no one had to discontinue
treatment because of side effects.
The treatment of hepatitis C is rapidly changing, Lawitz said.
"We are moving from an era of injectable medications with
significant toxicity to an era of all-oral combination pill therapy
that provides the promise of being well-tolerated with very high
rates of cure," he said.
The combination drug is still being evaluated in phase 3
clinical studies, so it is too soon to tell if it will receive U.S.
Food and Drug Administration approval or how it would be priced,
Because hepatitis C progresses without symptoms, the U.S.
Centers for Disease Control and Prevention recommends that adults
born from 1945 through 1965 get tested for the virus.
For more information on hepatitis C, visit the
U.S. National Library of Medicine.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.